Pharmacokinetics, metabolism and excretion of [¹⁴C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects

References

• Altamura C, Maes M, Dai J, Meltzer HY. (1995). Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 5:71–5
   PubMed Web of Science ®Google Scholar
• Altamura CA, Mauri MC, Ferrara A, et al. (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150:1731–3
   PubMed Web of Science ®Google Scholar
• Autry AE, Adachi M, Nosyreva E, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–5
   PubMed Web of Science ®Google Scholar
• Burrows GD, Maguire KP, Norman TR. (1998). Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 59:4–7
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Dolgin E. (2013). Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med 19:8
   PubMed Web of Science ®Google Scholar
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23–44
   PubMedGoogle Scholar
• Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
   PubMed Web of Science ®Google Scholar
• Jutkiewicz EM. (2006). The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162–9
   PubMedGoogle Scholar
• Katz MM, Tekell JL, Bowden CL, et al. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566–79
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214
   PubMed Web of Science ®Google Scholar
• Kucukibrahimoglu E, Saygin MZ, Caliskan M, et al. (2009). The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol 65:571–7
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143–50
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69:946–58
   PubMed Web of Science ®Google Scholar
• Maes M, Verkerk R, Vandoolaeghe E, et al. (1998). Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97:302–8
   PubMed Web of Science ®Google Scholar
• Mathews DC, Henter ID, Zarate CA. (2012). Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72:1313–33
   PubMed Web of Science ®Google Scholar
• Mauri MC, Ferrara A, Boscati L, et al. (1998). Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37:124–9
   PubMed Web of Science ®Google Scholar
• Mitani H, Shirayama Y, Yamada T, et al. (2006). Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30:1155–8
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Stahl SM, Krishen A, et al. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69:1287–92
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–17
   PubMed Web of Science ®Google Scholar
• Sanacora G, Zarate CA, Krystal JH, Manji HK. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426–37
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. (2013). Lanicemine: a low-trapping NMDA channel blocker producessustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 15:1–8
   Google Scholar
• Sanacora G, Johnson M, Khan A, et al. (2014). Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). 2014 NCDEU Annual Meeting (Poster #54)
   Google Scholar
• Stahl SM, Nierenberg AA, Gorman JM. (2001). Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 62:17–23; discussion 37–40
   PubMed Web of Science ®Google Scholar
• Thompson C. (2002). Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 17:S27–32
   Web of Science ®Google Scholar
• Zarate CA Jr, Mathews D, Ibrahim L, et al. (2013). A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry 74:257–64
   PubMed Web of Science ®Google Scholar
• Zenser TV, Lakshmi VM, Davis BB. (1999). Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos 27:1064–7
   PubMed Web of Science ®Google Scholar